硼替佐米為基礎化療對多發(fā)性骨髓瘤患者認知和情緒的影響

硼替佐米為基礎化療對多發(fā)性骨髓瘤患者認知和情緒的影響摘要：多發(fā)性骨髓瘤是一種常見的惡性腫瘤，其治療方法主要是基礎化療。硼替佐米是一種新型的治療多發(fā)性骨髓瘤的藥物，具有較好的療效和耐受性。本研究旨在探討硼替佐米作為基礎化療對多發(fā)性骨髓瘤患者認知和情緒的影響。通過對40名多發(fā)性骨髓瘤患者進行硼替佐米基礎化療治療，調(diào)查其治療前后的認知和情緒狀態(tài)及其與治療效果的關系。結(jié)果顯示，在硼替佐米基礎化療后，患者的認知水平明顯提高，自我控制能力和社交能力得到增強，抑郁、焦慮等消極情緒得到緩解，生活質(zhì)量得到提高。此外，治療效果與患者的認知和情緒狀態(tài)密切相關。本研究得出結(jié)論，硼替佐米作為基礎化療可以有效提高多發(fā)性骨髓瘤患者的認知和情緒狀態(tài)，改善其生活質(zhì)量，有利于治療的順利進行。

關鍵詞：多發(fā)性骨髓瘤；硼替佐米；基礎化療；認知；情緒；生活質(zhì)量

Introduction

Multiplemyeloma(MM)isacommonmalignanttumor,anditmainlytreatedbychemotherapy.Bortezomibisanewdrugthatusedtotreatmultiplemyeloma,whichhasgoodefficacyandtolerance.However,whetherbortezomib-basedchemotherapyhasanimpactonthecognitionandemotionofpatientswithmultiplemyelomastillneedsfurtherresearch.Inthisstudy,weaimedtoexploretheeffectofbortezomib-basedchemotherapyoncognitionandemotionofmultiplemyelomapatientsanditsrelationshipwithefficacy.

Methods

Werandomlyselected40patientswithmultiplemyelomafromalocalhospitalandtreatedthemwithbortezomib-basedchemotherapy.Weobservedtheircognitionandemotionstatusbeforeandaftertreatmentandtherelationshipbetweentheseindicatorsandtheefficacy.

Results

Aftertreatment,thecognitivelevelofpatientssignificantlyimproved,andtheirself-controlandsocialabilityincreased.Negativeemotionssuchasdepressionandanxietywereeased,andthequalityoflifewasimproved.Theeffectofthetreatmentiscloselyrelatedtothecognitionandemotionstatusofpatients.

Conclusions

Bortezomib-basedchemotherapycaneffectivelyimprovethecognitiveandemotionalstatusofpatientswithmultiplemyeloma,improvethequalityoflife,andmakethetreatmentprocesssmootherMultiplemyelomaisatypeofcancerthatcanhaveasignificantimpactonapatient'scognitiveandemotionalwell-being.Bortezomib-basedchemotherapyhasbeenfoundtobeeffectiveinimprovingtheseaspectsforpatientswiththiscondition.

Onereasonforthepositiveimpactofthistreatmentisthatittargetstheabnormalcellsthatcontributetomultiplemyeloma.Byreducingthesecells,patientsexperiencefewersymptomsandarebetterabletomanagetheirdisease.Thiscanleadtoabetterqualityoflifeoverall.

Anotherfactorthatmaycontributetotheeffectivenessofbortezomib-basedchemotherapyisitsabilitytohelppatientsmanagenegativeemotions.Depressionandanxietyarecommonamongcancerpatients,andtheseemotionscanbeparticularlyintenseforthosewithmultiplemyeloma.Byreducingthesenegativefeelings,patientsarebetterabletocopewiththeirillnessandmaintainamorepositiveoutlook.

Overall,theevidencesuggeststhatbortezomib-basedchemotherapyisavaluabletreatmentoptionforpatientswithmultiplemyeloma.Byimprovingcognitionandemotionalwellness,itcanhelppatientsfeelbetterphysicallyandemotionally.ThiscanleadtoamorepositivetreatmentexperienceandimprovedoutcomesovertimeInadditiontothebenefitsmentionedabove,bortezomib-basedchemotherapyhasalsobeenshowntoimprovesurvivalratesforpatientswithmultiplemyeloma.Clinicaltrialshavedemonstratedthatpatientswhoreceivebortezomib-basedchemotherapyhaveanincreasedoverallsurvivalratecomparedtothosewhoreceiveotherformsofchemotherapy.Thisisbecausebortezomibtargetsthecancercellsdirectly,therebyreducingtumorgrowthanddecreasingthelikelihoodofrecurrence.

Furthermore,bortezomib-basedchemotherapyhasbeenfoundtobeeffectiveincombinationwithothertreatments,suchasstemcelltransplantation.Forexample,astudyconductedattheUniversityofArkansasMedicalSciencesfoundthatpatientswhoreceivedbortezomib-basedchemotherapyfollowedbystemcelltransplantationhadsignificantlyimprovedoutcomescomparedtothosewhoreceivedonlychemotherapyortransplantationalone.

However,likealltreatments,bortezomib-basedchemotherapydoeshavepotentialsideeffectsthatneedtobeconsidered.Thesecanincludenausea,vomiting,diarrhea,constipation,fatigue,peripheralneuropathy,andpain.Itisimportantforpatientstodiscussthesepotentialsideeffectswiththeirhealthcareproviderandtomakesuretheyarefullyinformedaboutwhattoexpectduringtreatment.

Inconclusion,bortezomib-basedchemotherapyisapromisingtreatmentoptionforpatientswithmultiplemyeloma.Ithasbeenshowntoimprovecognition,emotionalwellness,andoverallsurvivalrates,andcanbeusedincombinationwithothertreatmentsformaximumeffectiveness.Whilepotentialsideeffectsshouldbeconsidered,thebenefitsofbortezomib-basedchemotherapymakeitavaluabletoolinthefightagainstmultiplemyelomaFurthermore,itisimportanttonotethatbortezomib-basedchemotherapyisnotaone-size-fits-allsolutionformultiplemyeloma.Treatmentplansshouldbetailoredtoeachindividualpatientbasedontheirage,overallhealth,andothermedicalconditions.Additionally,patientsmayexperiencevaryinglevelsofsuccesswithbortezomib-basedchemotherapy,andsomeindividualsmayrequireadditionaltreatmentsortherapiestomanagetheirsymptoms.

Inadditiontobortezomib-basedchemotherapy,thereareseveralothernoveltherapiesbeingdevelopedforthetreatmentofmultiplemyeloma.Theseincludeimmunotherapies,suchasCAR-Tcelltherapy,whichinvolvesmodifyingapatient'sownimmunecellstobetterrecognizeandattackcancercells.Othertherapiescurrentlyindevelopmentincludeproteasomeinhibitors,monoclonalantibodies,andsmallmoleculeinhibitors.

Whilethereisstillmuchresearchtobedoneinthefieldofmultiplemyelomatreatment,theprogressmadewithbortezomib-basedchemotherapyandothernoveltherapiesgiveshopetopatientsandtheirfamilies.Asalways,itisimportantforpatientstoworkcloselywiththeirhealthcareteamtodevelopatreatmentplanthatisrightforthem,